Abbott Laboratories Wednesday said it closed the acquisition of Piramal Healthcare Ltd.’s generic drugs unit. In May, Abbott had agreed to buy Piramal’s healthcare solutions business for about $3.7 billion, Abbott Laboratories said in a statement.
Inside these posts: Piramal
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
